
## CREST Scholar Orientation: Resources and Opportunities at NICHD

Esther Eisenberg, MD, MPH
Fertility and Infertility Branch
Division of Extramural Research
NICHD, NIH





#### **OUTLINE**

- NICHD Mission, Vision, Strategic Plan
- High Program Priority Areas
- Reproductive Medicine Clinical Trials Program at NICHD
  - RMN
  - New Reproductive Medicine clinical trial program (ConFIRM)
- Resources for clinical research at NICHD
  - Data and Specimen Hub (DASH)
  - RMN repository/ies
  - Funding opportunities for clinical research
- Clinical Reproductive Scientist Training (CREST) and you
  - Making the most of your CREST experience
  - Continuing your involvement in clinical research



## **NICHD Mission and Vision**

- To lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all.
- Healthy pregnancies, healthy children, healthy and optimal lives.



### **NICHD Organization**

- Office of the Director
- Division of Extramural Research (DER)
- <u>Division of Intramural Population Health Research</u>
   (<u>DIPHR</u>)
- Division of Intramural Research (DIR)
- National Center for Medical Rehabilitation Research (NCMRR)



## NICHD Strategic Plan 2020: Themes

- Understanding the Molecular, Cellular and Structural Basis of Development
- Promoting Gynecologic, Andrologic and Reproductive Health
- Setting the Foundation for Healthy Pregnancies and Lifelong Wellness
- Improving Child and Adolescent Health and the Transition from to Adulthood
- Ensuring Safe and Effective Therapeutics and Devices
- Cross-cutting Topics
  - Health disparities
  - Disease Prevention
  - Infectious Disease
  - Nutrition
  - Global Health



## **Extramural Scientific Branches (12)**

Contraception Research Branch (CRB)
Fertility and Infertility Branch (FIB)

Gynecologic Health and Disease Branch (GHDB)

Maternal and Pediatric Infectious Disease Branch

(MPIDB)

Pediatric Growth and Nutrition Branch (PGNB)

Population Dynamics Branch (PDB)

Pregnancy and Perinatology Branch (PPB)





## Fertility and Infertility Branch(FIB) Mission

 FIB's mission is to encourage, enable, and support research aimed at alleviating human infertility, uncovering new possible pathways to control fertility, and expanding fundamental knowledge of processes that underlie human reproduction.



## FIB High Program Priority Areas

- Early Pregnancy Loss and Predictors of Pregnancy Outcome
- Fertility and Overall Health
- 'Omic Approaches to Investigate Infertility Pathogenesis
- Nutrition, Metabolism, Circadian Rhythms, and Reproduction
- Early Reproductive Transitions
- In addition, applications for FIB that propose technical innovations or that address health disparities or involve diverse populations (race, ethnicity, disability, or patients with diseases not previously recognized to have a fertility/infertility component) will have higher priority, even if they do not address one of the science areas listed in the following priorities.
- https://www.nichd.nih.gov/about/org/der/branches/fib



## FIB Examples of HPP topics

- Gamete quality and pre-placental processes as they relate to the etiology of early pregnancy loss
- Transgenerational epigenetic inheritance
- The relationship of fertility status to overall health and disease
- Genetic basis of idiopathic male and female fertility
- Impact of nutrition and metabolism on fertility
- Identification of biomarkers to study reproductive transitions
- Development of innovative technologies and model systems that can advance progress in reproductive biology and medicine

## **Translation Continuum**






#### RMN/ConFIRM and CREST

- Interaction between CREST scholar and clinical trial Pls
- CREST scholars have participated in RMN studies as co-Investigators at CREST 'ancillary' sites
- RMN PIs and coordinators provided guidance for navigating IRB, grants offices, recruiting participants and conducting trials
- CREST may use RMN or other data to investigate new questions of clinical importance
- Increase knowledge through publications and presentations

## Continuum of Clinical Research Mapped on Translational Blocks





## Reproductive Medicine Network


- Funded by NICHD from 1989-2019
  - Cooperative multi-center clinical trial network
- To carry out large clinical trials in the area of male and female infertility and reproductive diseases and disorders.
- Goal: Trials that have immediate impact on clinical practice
- New Model is a multi-investigator linked R01 program
  - Reproductive Medicine Clinical Trial Program/CONsortia for Infertility and Reproductive Medicine (CONFIRM)



## Reproductive Medicine Network: 2013-2018+1

- Multicenter Clinical Trial Network (<u>www.c2s2.yale.edu/rmn</u>)
  - 6 Main Sites + 1 DCC (Data Coordinating Center)
  - 6 Ancillary Sites (modeled on CREST Collaboration)
  - Steering Committee Chair appointed by FI Branch/NICHD
- Goal
  - To develop novel and more effective strategies for diagnosis, treatment, and prevention of infertility and underlying causes
  - To evaluate new interventions for treatment of infertility
  - To more rapidly bring scientific discoveries to the bedside
- Studies/clinical trials on female infertility, male infertility incl comparative effectiveness of IVF standard treatments
- Geographic Diversity and Inclusion
- Data and Specimen Repository
  - data for completed trials in DASH
  - Specimen repositories at PI Institutions
- Resource for CREST Scholars for mentorship and secondary analyses

## **Reproductive Medicine Network Sites**





## **RMN Protocols Completed in Last Cycle**

- ACTORNOT -- Optimal Treatment for Women with a Persisting Pregnancy of Unknown Location: Active Treatment versus No Treatment The "ACTORNOT" Trial (Barnhart-PI)
- FIT-PLESE -- Improving Reproductive <u>Fit</u>ness with <u>Pretreatment with Lifestyle Modification in Obese Women with Unexplained Infertility: FIT-PLESE (Legro-PI)
  </u>
- MOXI -- Males, Antioxidants, and Infertility--RCT of the effect of antioxidants on semen parameters and male fertility (Steiner-PI)



# Optimal Treatment of Persisting Pregnancy of Unknown Location: RCT of Women at Risk for an Ectopic Pregnancy Active Treatment vs. Expectant Management (No Treatment): The "ACTORNOT TRIAL-Barnhart(PI)

- Pragmatic randomized clinical trial evaluating optimal management for women with a pregnancy of unknown location
  - expectant management
  - empiric methotrexate
  - uterine evacuation
- 1:1:1 randomization
- Outcome is change of plan from initial strategy
- Secondary outcome -- efficacy and cost analysis
- Sample size goal -275

### FIT-Plese Overview

Obese Women (BMI ≥30 and Age ≤ 40y) with Unexplained Infertility (N = 380)

Phase I Lifestyle: 16 weeks

Intensive Lifestyle Modification: Weight Loss AND Increased Physical Activity (N = 190)

Standard Lifestyle Modification: Increased Physical Activity ( N = 190)

Phase II: Infertility Treatment

3 cycles of Ovarian Stimulation with Clomiphene /Insemination (Clamp physical activity and weight during this phase)

Phase III: Pregnancy Pregnancy ( 3 visits): One per trimester for weight, blood pressure, and glycemic measures

Phase IV: Infancy Primary Outcome: Good Birth Outcome: Healthy singleton or twin Live Birth (≥ 37 weeks, 2500-4000g, no major anomaly)

Infant Follow up



#### **MOXI Overview**

- Study Population: 790 Couples with male factor infertility
- Inclusion criteria:
  - Sperm concentration ≤15 Million/ml or, total motility ≤40%, or normal morphology (Kruger) ≤4%, or DNA fragmentation (SCSA) >25%
  - Females (≤38 yo) with tubal patency, regular menstrual cycles, and evidence of ovulation
- Primary Outcome: Live birth
- Secondary:
  - Pregnancy, time-to-pregnancy, miscarriage
  - Subgroup analyses (type of sperm abnormality)
  - Internal Pilot
    - 120
    - Changes in semen parameters



#### **Other RMN Protocols**

#### Recent

- PrISICE Pilot-- Preimplantation Genetic Screening (PGS) and Deferred Transfer of Cryopreserved Embryos over "Freeze-Only" Deferred Transfer without PGS or Immediate Embryo Transfer during a "Fresh" In Vitro Fertilization Cycle (Cedars, Coutifaris-PIs)
- ENDOmarker -- Evaluation, Validation and Refinement of Noninvasive
   Diagnostic Biomarkers for Endometriosis (Barnhart-PI)

#### Previous

- PPCOS I Pregnancy in Polycystic Ovary Syndrome I (CC vs. Met vs. CC+Met
- PPCOS II Pregnancy in Polycystic Ovary Syndrome II (CC vs. Letrozole)
- AMIGOS Assessment of Multiples Gestations with Ovarian Stimulation (CC vs. Letrozole vs. Gonadotropins) and IUI
- PSY-FI PsychoSocial Family Issues associated with Multiple Gestations
- PhOx RCT of Physiologic (3%) vs. Standard Oxygen Tension for IVF



## Reproductive Medicine Network: 2013-2018+1

- Multicenter Clinical Trial Network
  - 6 +1 Main Sites
  - 6 Ancillary Sites (modeled on CREST Collaboration)
  - SC Chair appointed by FI Branch/NICHD

#### Goal

- To develop novel and more effective strategies for diagnosis, treatment, and prevention of infertility and underlying causes
- To evaluate new interventions for treatment of infertility
- To more rapidly bring scientific discoveries to the bedside
- Studies/clinical trials on female infertility, male infertility including comparative effectiveness of IVF standard treatments-Concept protocols reviewed~delayed onset
- AB and DSMB appointed by NICHD Director
- Geographic Diversity and Inclusion
- Data and Specimen Repository funded through DCC
- Resource for CREST Scholars for mentorship and secondary analyses



## ConFIRM—Consortia for Reproductive Medicine and Infertility

- Multi-PI linked R01 Consortia
  - R01 applications with common clinical trial protocol
- DCC included in linked application with same clinical trial protocol. DSMB is constituted in DCC R01.
- PI may identify ancillary affiliated clinical site or subcontract with distant site.
- PI may be a part of more than one (maximally 3) multi-PI linked application.
- Separate maximal site infrastructure costs and protocol capitated costs.



## Reproductive Medicine Collaborative Clinical

Trials Program (Collaborative R01)			
PI/MPI	Institution	Consortium – n/N	Special Features
V. Baker/J. Segars	Johns Hopkins University	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 1/3	DCC, sIRB
K. Hansen	Univ of Oklahoma HIth Sciences Ctr	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 2/3	
R. Lathi/V. Winn	Stanford University	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 3/3	
H. Taylor/H. Zhang	Yale University	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –1/4	DCC, sIRB


K. Hansen	Univ of Oklahoma HIth Sciences Ctr	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 2/3	
R. Lathi/V. Winn	Stanford University	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 3/3	
H. Taylor/H. Zhang	Yale University	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –1/4	DCC, sIRB
N. Santoro	Univ of Colorado Denver	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –2/4	
J. Robins	Northwestern Univ at Chicago	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –3/4	
S. Young	Univ North Carolina	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –4/4	

K. Hansen	Univ of Oklahoma HIth Sciences Ctr	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 2/3	
R. Lathi/V. Winn	Stanford University	RCT of programmed or natural cycle for frozen embryo transfer – NatPro 3/3	
H. Taylor/H. Zhang	Yale University	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –1/4	DCC, sIRB
N. Santoro	Univ of Colorado Denver	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –2/4	
<mark>J. Robins</mark>	Northwestern Univ at Chicago	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –3/4	
S. Young	Univ North Carolina	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –4/4	
J. Segars/V. Baker	Johns Hopkins University	RCT of EGCG to improve fertility in women with uterine fibroids – 1/4	sIRB
H. Taylor/Zhang	Yale University	RCT of EGCG to improve fertility in women with uterine fibroids —	DCC
F. Gonzalez/A.Al-	<b>Univ Illinois Chicago</b>	RCT of EGCG to improve fertility in women	

	<b>Denver</b>	with endometriosis – PREGNANT –2/4	
J. Robins	Northwestern Univ at Chicago	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –3/4	
S. Young	Univ North Carolina	Pre-IVF tx with GnRH antagonist in women with endometriosis – PREGNANT –4/4	
J. Segars/V. Baker	Johns Hopkins University	RCT of EGCG to improve fertility in women with uterine fibroids – 1/4	sIRB
H. Taylor/Zhang	Yale University	RCT of EGCG to improve fertility in women with uterine fibroids —	DCC
F. Gonzalez/A.Al-	Univ Illinois Chicago	RCT of EGCG to improve fertility in women with uterine fibroids –	



RM/I Clinical Trial Program as Multi-PI linked R01s (RMCTP-ConFIRM)





## Advantages of Linked R01s

- Sites with low priority scores can be excluded prior to funding. However, this may cause recruitment challenge.
- Pls can be part of more than one clinical trial.
- Each PI has independent grant, equal standing.
- No COI with Project Scientist.
- Independent review and prioritization of protocols by study section rather than by SC and AB



## Disadvantages of Linked R01s

- Time to initiate studies is long, with administrative delays
  - Protocols were not fully developed.
  - Single IRB review required agreements between institutions.
  - DSMB was constituted after funding.
- Inefficiencies-Time consuming for Program staff
  - Multiple monthly SC meetings
  - Multiple DSMB meetings
- Less collaborative since there is only 1 lead PI in each consortium. Opportunity to bring consortia together to establish a network is delayed due to COVID and delayed starts of recruitment
- Structure is less conducive to provide opportunities for CREST Scholars to receive mentorship
- Structure less nimble to add timely ancillary studies



## Linked R01s vs. Cooperative Agreements

	Ennited ite ie ve. ecoperative rigidemente			
	Linked R01s	CAs		
Pls	Focused on single trial; less interaction; not as engaged; not true network	Network; focused on several trials, consideration of ancillary questions		

**DSMB** 

SC

DCC Multiple DCCs-one for each trial; increased cost

Appointed by DCC; independent of

NICHD/sponsor Multiple DSMB, so extra meetings for PO

AB

In essence SRG serves this purpose wrt protocols and prioritization of clinical trials

SC Lead PI and Study team; no true SC;

monthly meetings for each consortium None; Program Officer may interact in

Chair similar role Rep of Program Officer-not involved in all activities Monthly meetings for each MICHD

Single DCC-less duplication

More efficient processes Appointed by NICHD Directorcould be perceived as COI; Single

DSMB for all network trials-more efficient Appointed by NICHD Director;

available to advise on other issues throughout grant period

SC-seat of decision making; monthly and quarterly meetings

SC Chair-added knowledge and perspective; keeps SC on track

Project Scientist-involved in all aspects of the network: can



Linked Ruis vs. Cooperative Agreements			
	Linked R01s	CAs	
Study	Best protocols selected by SRG-may	PS has vote to prioritize proto	

topics

focus on only one aspect of infertility. Program recs to NACCHD are constrained by priority score

ocols PO and FI Branch Chief can advise on branch priorities

Risks

Less program influence on productivity Delayed onset: Protocol needed to be

Time to initiation developed; sIRB approvals delayed; of DSMB needed to be constituted; FDA studies IND needed; only 1 study has recruited

Delayed onset: Concept protocols needed to be prioritized, revised, approved by AB and DSMB-similar timeline to start

1 subject to date Ancillary Studies detailed in grant applications

SC can pivot to study timely topics if urgent

COL

studies CREST Not directly involved. Hope to get consensus approval to collaborate

CREST Scholars involved in recruitment and secondary analyses



## **NICHD Resources for Clinical Research**

- Data and Specimen Hub (DASH)
- RMN Biorepositories
- Training
  - Bioethics course given annually
  - R25 CREST Program
- Career Development Awards
- Funding for pilot studies and secondary analysis to obtain preliminary data (R03)

#### DASH Data and Specimen Hub

- Centralized resource for researchers to share de-identified data from studies funded by NICHD. DASH also serves as a portal for requesting biospecimens from selected studies in DASH.
- Data sharing launched in August 2015; biospecimen request launched in March 2019
- Aims to accelerate scientific findings to ultimately improve human health



#### **Study Topics in DASH**

Adrenal Gland Disorders

Amenorrhea

Autism Spectrum Disorders

Birth Defects

Breastfeeding &

Breast Milk\*

Cerebral Palsy

Child Health\*

Children's Bone Health & Calcium

Delayed Puberty

Diabetes

Driving Risk

Early Learning

Fertility Problems

High-Risk Pregnancy

HIV/AIDS\*

Infant Care &

Health \*

Infant Mortality

Infertility & Fertility

Labor & Delivery

Men's Reproductive

Health

Menkes Disease

Necrotizing Enterocolitis Neuroscience

Obesity & Overweight

Obstetrics

Pediatric Injury

Pelvic Floor Disorders

Pharmacology

Preconception & Prenatal Care

Preeclampsia & Eclampsia

Pregnancy\*

**Pregnancy Loss** 

Preterm Labor

& Birth\*

Primary Ovarian Insufficiency

Puberty &

Precocious Puberty

Rehabilitation Medicine

Sleep

Spinal Cord Injury

Stillbirth

Stroke

Sudden Infant Death

Syndrome

Traumatic Brain

Injury

Turner Syndrome
Women's Health\*30

https://dash.nichd.nih.gov

#### DASH Data and Specimen Hub

- DASH has added a new function: managing requests for NICHD biospecimens.
- While not a biorepository itself, DASH serves as a portal for access to biospecimens associated with DASH data collections.
- Investigators worldwide can now request both biospecimens and data for secondary analyses; other than the costs of preparing and shipping biospecimens, these specimens are free to investigators.
- Studies with biospecimens currently available include:
  - Genomic and Proteomic Network for Preterm Birth Research (GPN) – three studies
  - NICHD International Site Development Initiative (NISDI)
     four studies
  - Mothers and Infants Cohort Study (MICS)
  - National Children's Study (NCS)

## **Study Topics Areas of Current Biospecimens**

Breastfeeding and Breast Milk

Child Health

**HIV/AIDS** 

Infant Care and Infant Health

Pregnancy Preterm Labor and Birth

Women's Health

## **Currently Available Biospecimens**

Amniotic fluid

Blood

Breast Milk

**Buffy Coat** 

Cord Blood (Buffy

Coat, RBC, Plasma,

Serum)

DNA/RNA/Proteins

Environmental

Samples

Erythrocytes (RBC)

Hair

Lymphocytes

Meconium

Nail

Saliva

Serum/Plasma

Tissue samples

Urine

Vaginal Fluid



#### **Process for CREST Scholars to Access DASH data**

#### What you need to do:

- 1. Register as a user in DASH and confirm your registration through the link in the Registration Confirmation email that you will receive from DASH. \*\*\*Note: You must select "University of Colorado Denver" as your institution when you register as a CREST Scholar.
- 2. Email Dr. S after you register in DASH. She will then log into DASH and add you as an 'Affiliate' user and inform you that you have been added.
- 3. You can access study data through the DASH Workbench. Login to DASH and click on the Workbench icon located on the top menu bar of NICHD DASH.
- 4. The study data will be available in your Inbox on the Workbench, where you may select individual items and Download selected items from your Inbox to your computer.



## **Mentorship Matters**

- Teaching mentee the "rules of the game"
- Providing resources
  - References to others, secretarial support
- Gain access to closed academic circles
- Advocating for mentee
- Providing networking opportunities
- Helping the mentee to promote themselves



## **Mentorship Matters**





### Making the Most of CREST

- Find a research topic you're passionate about!
- Clinical research is TEAM Science-find ways to collaborate
- Chart a path
- Create timeline and be accountable
- Find mentors
- Network and collaborate
- Find sources of funding
  - CTSA, professional societies, foundations, etc.
  - Consider small grant (i.e. R03) opportunities
  - Consider career development (K23) path

#### **THANK YOU!**

